Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Land & Improvements: 2011-2022

Historic Land & Improvements for China Pharma Holdings (CPHI) over the last 12 years, with Dec 2022 value amounting to $404,427.

  • China Pharma Holdings' Land & Improvements fell 7.12% to $389,808 in Q2 2023 from the same period last year, while for Jun 2023 it was $389,808, marking a year-over-year decrease of 7.12%. This contributed to the annual value of $404,427 for FY2022, which is 8.46% down from last year.
  • According to the latest figures from FY2022, China Pharma Holdings' Land & Improvements is $404,427, which was down 8.46% from $441,783 recorded in FY2021.
  • In the past 5 years, China Pharma Holdings' Land & Improvements registered a high of $441,783 during FY2021, and its lowest value of $403,755 during FY2019.
  • For the 3-year period, China Pharma Holdings' Land & Improvements averaged around $425,964, with its median value being $431,681 (2020).
  • Its Land & Improvements has fluctuated over the past 5 years, first climbed by 6.92% in 2020, then declined by 8.46% in 2022.
  • China Pharma Holdings' Land & Improvements (Yearly) stood at $409,612 in 2018, then fell by 1.43% to $403,755 in 2019, then grew by 6.92% to $431,681 in 2020, then climbed by 2.34% to $441,783 in 2021, then dropped by 8.46% to $404,427 in 2022.